William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.
Gradishar says the trial compared the combination of a taxane, trastuzumab, and the mTOR inhibitor everolimus to treatment with a taxane plus trastuzumab. It was thought that the addition of an mTOR inhibitor might help against trastuzumab resistance, Gradishar says.
While the trial found that the addition of the mTOR inhibitor did not show a significant improvement for the entire population, the HR-negative patients seemed to gain some benefit from the addition of everolimus, Gradishar says.
Gradishar says strategies for overcoming trastuzumab resistance or anti-HER2 therapy resistance still requires a great deal of work.
<<< View more from the 2014 San Antonio Breast Cancer Symposium